Novo Nordisk updates analyst targets, shares stay in S&P 500 focus
23.06.2026 - 14:28:59 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 14:25.
Novo Nordisk A/S (DK0062498333) continues to draw strong analyst attention, with the ADR listed on the NYSE under the ticker NVO and the core listing in Copenhagen under NOVO B. On the Danish market, the B-shares last traded around 306.60 Danish kroner, keeping the pharma heavyweight firmly in the S&P 500 peer frame alongside Eli Lilly.
What recent analyst notes say
Analyst coverage for Novo Nordisk remains active, with Deutsche Bank and Berenberg among the houses updating their Danish price targets in recent weeks. Deutsche Bank reiterates a Hold rating with a target around 290 kroner, while Berenberg maintains a Buy stance and lifts its target to about 325 kroner, according to a recent German market summary that compiles these flashes.
The consensus view reflected on platforms such as MarketBeat and other aggregators still leans positive, with multiple Buy ratings and only a minority of Hold recommendations for the ADR. Novo Nordisk features regularly in U.S. market commentary given its role in the global obesity treatment segment, where its Wegovy and Ozempic franchises are frequently cited as key growth drivers.
How the shares trade in New York and Europe
On the NYSE, Novo Nordisk ADRs most recently closed at 45.90 US dollars, up 6.27 percent in the previous regular session before ticking slightly lower in post-trade, according to price data collated by Arincen. Extended trading showed the ADR changing hands around 45.63 to 46.51 dollars, underlining continued liquidity in U.S. dealings.
In Europe, German trading venues like Tradegate quote the Novo Nordisk shares in euros, with recent indications around the low 40-euro range per share on platforms such as Onvista. The Danish core listing in Copenhagen, tracked by the Financial Times market data service, shows the NOVO B line trading above 300 kroner and more than 35 percent above its 52-week low of 224.25 kroner.
All news and analysis on the Novo Nordisk shares
Further company reports, price data and regulatory disclosures on Novo Nordisk can be found in the dedicated topic section and via the investor relations pages.
Where Novo Nordisk makes its money
Novo Nordisk generates the bulk of its revenue from diabetes care and obesity treatments, led by blockbuster GLP-1 products such as Ozempic for type 2 diabetes and Wegovy for weight management. The group also sells insulin products, including long-acting formulations, and maintains a smaller but established business in rare disease therapies.
Where the stock trades today
The Novo Nordisk ADRs (DK0062498333) most recently closed on the NYSE at 45.90 US dollars on 2026-06-22, while the Danish B-shares traded around 306.60 Danish kroner in Copenhagen on the same date.
Key data on the Novo Nordisk shares
- Company: Novo Nordisk A/S
- ISIN: DK0062498333
- WKN: A3EU6F
- Ticker: NVO / NOVO B
- Trading venue: NYSE (ADR) / Copenhagen (core listing)
- Price (as of 2026-06-22, 16:00): 45.90 USD (ADR)
- Market cap: 203,242,010,868 USD (as of 2026-06-22)
- Sector / industry: Health Care / Pharmaceuticals
- Index membership: S&P 500 (ADR), OMX Copenhagen benchmarks
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities.
